Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Harmaline

Plain-language summaryIntrigue 60 / 100

Harmaline is one of the three main beta-carboline alkaloids in the ayahuasca vine (Banisteriopsis caapi) and Syrian rue (Peganum harmala). Its critical pharmacological role is reversible MAO-A inhibition, which is what allows oral DMT to reach the brain in ayahuasca brews (without an MAO-A inhibitor, gut MAO destroys oral DMT before it can act centrally). Harmaline by itself produces vivid closed-eye visual imagery at high doses but is not a classical psychedelic. The reversible MAO inhibition is safer than the irreversible MAO inhibitors used as antidepressants but still creates real food and drug interaction risks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

34/100

A reference MAO-A inhibitor and tremor-model tool with limited novelty and thin standalone clinical signal

Harmaline is one of those compounds that earns its place in a research library not because it’s novel or therapeutically exciting, but because it does a specific job that’s hard to replicate. The beta-carboline skeleton, shared with harmine and tetrahydroharmine, has been pulling double duty in ethnobotanical and neuropharmacology research for decades, and harmaline’s particular profile, reversible MAO-A inhibition with good selectivity over MAO-B (Ki around 5 µM at human MAO-A, over 100-fold selectivity), makes it a reference compound worth having around.

The MAO-A story is the center of gravity here. As one of the primary harmala alkaloids in ayahuasca preparations, harmaline’s pharmacological role is well understood: it inhibits intestinal and hepatic MAO-A, which would otherwise degrade DMT before systemic absorption. That’s genuinely important for understanding the brew’s oral bioavailability, but it also means harmaline’s most studied context is inseparable from a multi-compound mixture. Isolating its specific contributions to human pharmacology in that context is messy, and standalone human data on harmaline is thin.

What we find more interesting from a bench standpoint is the tremor model. Harmaline-induced tremor in rodents is one of the few pharmacologically validated animal models of essential tremor, and it’s been used across dozens of labs to probe the cerebello-olivary system, test tremor-suppressing drug candidates, and understand the oscillatory physiology underlying the condition. For labs working on motor control or essential tremor biology, harmaline isnt a curiosity, it’s infrastructure.

Outside the tremor work, the compound has some utility as a broader beta-carboline pharmacology probe. The class hits multiple targets at varying concentrations, including sigma receptors and some NMDA interactions at higher doses, and harmaline lets you explore that pharmacology with a reversible agent that clears reasonably fast (plasma half-life roughly 2 to 3 hours). That’s useful for experimental designs where you need to avoid prolonged MAO-A suppression and want a cleaner washout window than irreversible inhibitors allow.

What limits the score is that the mechanism landscape is mature. Reversible MAO-A inhibition as a pharmacological concept is not new ground; moclobemide covers the clinical story more cleanly, harmine covers much of the same structural territory with arguably more CNS penetration literature, and the therapeutic promise of harmaline specifically is low. The translational signal outside of ayahuasca context is weak. We think this one belongs in the library as a reference and model compound, not as a frontier research target. The score reflects that honestly.

Novelty

20

Mechanism promise

35

In-category differentiation

32

Evidence quality

45

Translational signal

25

Research bench value

62

Rationale Harmaline’s score is driven by its genuine but narrow bench utility: the harmaline-induced tremor model is a pharmacologically validated rodent model of essential tremor used across many labs, and its rMAO-A selectivity profile (Ki ~5 µM, >100-fold over MAO-B) makes it a useful reference compound. Novelty, mechanism, differentiation, and translational scores are low because the pharmacology is mature, the clinical picture outside the ayahuasca context is thin, and better alternatives exist for most of what it does.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-carboline reversible MAO-A inhibitor

A beta-carboline alkaloid from Peganum harmala and Banisteriopsis caapi; a reversible MAO-A inhibitor and component of ayahuasca.

Abstract

Harmaline (4,9-dihydro-7-methoxy-1-methyl-3H-pyrido[3,4-b]indole; CAS 304-21-2; molecular formula C13H14N2O; molecular weight 214.27) is a beta-carboline alkaloid isolated from Peganum harmala (Syrian rue) and Banisteriopsis caapi (ayahuasca vine). The compound is a reversible MAO-A inhibitor (Ki approximately 5 microM at human MAO-A) with greater than 100-fold selectivity over MAO-B; this reversible MAO-A inhibition is central to the pharmacology of ayahuasca, where harmaline (and harmine) prevent intestinal breakdown of the DMT in the brew, allowing oral activity. Harmaline itself has serotonergic and tremorgenic effects in animals and mild psychoactive effects in humans. Plasma half-life is approximately 2 to 3 hours. Used as a reference reversible MAO-A inhibitor and as a research probe for beta-carboline pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-337Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Beta-Phenylethylamine (PEA)

Our opinion on this compoundNiche research probe

41/100

Endogenous TAAR1 reference compound with poor pharmacokinetics that limit utility beyond the trace amine niche

Look, PEA is genuinely interesting biology and a genuinely limited research tool, and that tension defines the score.

The TAAR1 story is real. Trace amine-associated receptor 1 is one of the more intellectually honest targets to emerge in monoamine pharmacology in the last two decades. It’s a GPCR that responds to endogenous trace amines and modulates dopaminergic and serotonergic neurotransmission without acting directly on those receptors. Thats a mechanistically clean and novel angle, and PEA is the canonical endogenous agonist with a Ki of roughly 700 nM at human TAAR1. The field has genuine traction: ulotaront (SEP-363856), a synthetic TAAR1 agonist developed by Sunovion, completed phase 2 trials in schizophrenia with signal that got people’s attention, and Roche’s RO5166017 has been a workhorse probe in preclinical TAAR1 circuit work. That context upgrades PEA from an old supplement to an endogenous reference compound for an active receptor target.

The problem is the pharmacokinetics, and it’s a serious one. Plasma half-life sits around five to ten minutes owing to rapid MAO-B-mediated degradation. Exogenous oral PEA is largely inactive as a result; meaningful tissue exposure requires MAO-B inhibition, and the selegiline combination used in preclinical trace amine work introduces confounders that make clean TAAR1-attribution difficult. When you compare PEA to synthetic TAAR1 probes with proper selectivity profiles and half-lives long enough to actually run behavioral assays, PEA becomes a baseline reference rather than a primary tool. It tells you where the endogenous system sits; it doesn’t let you interrogate TAAR1-dependent physiology without significant pharmacokinetic caveats layered on top.

The evidence base reflects that limitation honestly. There’s a meaningful multi-lab neurochemistry literature on PEA’s role in trace amine physiology, and some recurring correlational human data, specifically urinary PEA excretion correlations with depressive episodes that thread through the older psychiatric literature. Effect sizes are modest and the mechanistic link remains indirect. What there isn’t is a clean clinical program built around PEA itself, because the PK problem has always redirected pharmaceutical development toward more stable TAAR1 agonists rather than the endogenous parent compound.

We think the bench value here is real but narrow. If you’re running a TAAR1 biology program, you need PEA as your endogenous reference; it’s what every TAAR1 paper anchors comparisons against. That’s genuine utility and we credit it. But if you’re not specifically in the trace amine space, the compound adds little that a better-designed synthetic probe couldn’t do more cleanly. The supplement community has built a reputation around it that the pharmacological picture doesn’t support, and we score accordingly.

Novelty

28

Mechanism promise

60

In-category differentiation

38

Evidence quality

44

Translational signal

28

Research bench value

52

Rationale PEA scores on mechanism interest because TAAR1 is a genuinely active research target with real pharma investment, but its extremely short half-life and the availability of superior synthetic TAAR1 probes constrain bench value to the narrow endogenous-reference role; supplement-market hype inflates its reputation well past the pharmacological reality.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous trace amine / TAAR1 agonist

An endogenous trace amine; a TAAR1 agonist found at low concentrations in mammalian brain; structurally the parent of amphetamine.

Abstract

Beta-phenylethylamine (PEA; 2-phenylethylamine; CAS 64-04-0; molecular formula C8H11N; molecular weight 121.18) is an endogenous trace amine produced by decarboxylation of L-phenylalanine. The compound is found at low concentrations in mammalian brain (nM range) and in dietary sources including chocolate, cheese, and certain fermented foods. PEA is the prototype TAAR1 agonist (Ki approximately 700 nM at human TAAR1) with secondary effects on monoamine release and inhibition of MAO-B. Plasma half-life is extremely short (approximately 5 to 10 minutes) owing to rapid MAO-B-mediated degradation; exogenous oral PEA is therefore largely inactive without MAO-B inhibition (selegiline combination is used to extend duration). Behavioral and physiological effects parallel amphetamine but with shorter duration and lower potency. Used as the canonical endogenous TAAR1 agonist in trace amine research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-335Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Alpha-Ketoglutarate (AKG)

Plain-language summaryIntrigue 65 / 100

Alpha-ketoglutarate (AKG) is a TCA cycle intermediate that has shown lifespan extension in mouse studies. Calcium AKG (Ca-AKG) is sold as a longevity supplement, popularized by Rejuvant. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

44/100

Old metabolite with a genuinely interesting epigenetic aging angle, but thin human evidence and COI-clouded pilot data keep it mid-tier

Look, AKG has been sitting in the TCA cycle since the first organisms figured out oxidative metabolism. Calling it novel is a stretch. But there’s a specific modern angle that deserves a serious look: AKG is a required co-substrate for the 2-oxoglutarate-dependent dioxygenase (2-OGDD) superfamily, which includes TET enzymes driving DNA demethylation, JmjC-domain histone demethylases, and prolyl hydroxylases feeding into HIF pathway regulation. When plasma and tissue AKG levels fall with age, which they do, you’re potentially starving a set of enzymes that maintain epigenetic fidelity. That’s a real mechanistic hypothesis, not just “it’s in the Krebs cycle so it must be good.”

The animal data is what put Ca-AKG on the map for longevity researchers. The 2020 work (Shahmirzadi et al., Cell Metabolism) showed Ca-AKG supplementation at 2 percent chow concentration extended healthspan and lifespan in mice, with reduced senescence markers and attenuated inflammaging signals. The C. elegans results are older and show up to 50 percent lifespan extension, though worm data translates poorly. The mouse work is from a real lab with real methodology, but it’s essentially one study from one group at this point.

The human pilot is where things get complicated. Tian et al. 2022 (Aging journal, n=42, open-label) reported roughly 8 years of epigenetic age reduction using Horvath-type methylation clocks after Rejuvant supplementation. What we like: it’s actual human data with a pre-specified methylation endpoint, which is rare in this space. What we dont like: the study is from the Rejuvant commercial team, its open-label with no placebo arm, and epigenetic clocks as primary endpoints remain contested even among clock developers. Replicated, blinded data from independent groups simply doesnt exist yet.

As a bench tool, AKG has real utility for investigators studying 2-OGDD biology or aging-related epigenetic drift. If you’re running a research program on TET enzyme activity, substrate availability experiments are straightforward and informative. The compound is easy to source, stable, and inexpensive. That’s worth something, even if it’s not a sophisticated probe.

We think the 2-OGDD epigenetic aging story is the most interesting thing going on with this compound, and it’s underexplored relative to the NAD+/sirtuin and mTOR spaces that absorb most longevity research attention. But the honest assessment is that the human evidence is one small, conflict-laden pilot, and the mouse mechanism is incompletely worked out. This is a compound worth watching, not one to prioritize. If independent groups replicate the methylation clock findings in a blinded design, the score goes up meaningfully.

Novelty

38

Mechanism promise

58

In-category differentiation

45

Evidence quality

37

Translational signal

35

Research bench value

45

Rationale AKG would normally sit under the foundational-metabolite cap, but the 2-oxoglutarate-dependent dioxygenase story for epigenetic aging qualifies as a novel indication with real (if preliminary) human signal, lifting the cap exemption. Scores land in the low-40s because the mechanism is compelling but the evidence base is thin and largely consortium-sourced.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

TCA cycle intermediate / 2-oxoglutarate

A TCA cycle intermediate sold as calcium alpha-ketoglutarate (Ca-AKG) for longevity applications based on extension of lifespan in mice and worms.

Abstract

Alpha-Ketoglutarate (AKG, 2-oxoglutarate; CAS 328-50-7; molecular formula C5H6O5; molecular weight 146.10) is a tricarboxylic acid cycle intermediate that declines with age in plasma and tissues. The compound is a substrate for the 2-oxoglutarate-dependent dioxygenase family of enzymes (including DNA and histone demethylases, prolyl hydroxylases, and TET enzymes), placing it at a hub of cellular regulation. AKG supplementation extends lifespan in C. elegans (up to 50 percent) and in mice when given as the calcium salt at 2 percent in chow. The mechanism in mice is incompletely characterized but appears to involve reduced cellular senescence, improved metabolic flexibility, and reduced inflammaging markers. Sold as calcium alpha-ketoglutarate (Ca-AKG, Rejuvant) for supplemental use. Doses are typically 500 to 2000 mg per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-105Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Quercetin

Plain-language summaryIntrigue 62 / 100

Quercetin is a natural flavonoid found in onions, apples, and capers. It is one half of the dasatinib-quercetin (D+Q) senolytic combination. Quercetin alone has anti-allergic and anti-inflammatory effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

38/100

Established senolytic flavonoid with a real D+Q role but clearly outclassed by fisetin standing alone

Look, quercetin isn’t a bad compound. It’s just not a particularly exciting one right now, and the rubric rewards excitement. It’s a flavonoid you’ll find in every health food store, in onions, in apples. Researchers have been poking at it since the 1990s across allergy biology, NF-kB signaling, antioxidant assays, and a half-dozen other directions. None of those lines produced anything that made quercetin the center of a research program.

The senolytic angle changed the picture, a little. The Kirkland and Niedernhofer group’s work canonized the dasatinib-plus-quercetin (D+Q) regimen as the reference senolytic protocol, and that gave quercetin a specific, real identity in the aging research space. Small Mayo Clinic trials in idiopathic pulmonary fibrosis and diabetic kidney disease showed hints of a signal. The protocol is being used in ongoing NIA-funded trials. Thats genuinely meaningful. What we don’t like is that quercetin is the junior partner in that combination. Dasatinib is doing the mechanistic heavy lifting on the Bcl-2 and Bcl-xL senescence survival pathways. Quercetin contributes, but isolating its contribution from dasatinib in most D+Q datasets is difficult, and its standalone senolytic potency is explicitly weaker than fisetin in head-to-head comparisons.

The pharmacokinetics are a real problem for bench work. Oral bioavailability of the free aglycone is poor, with plasma concentrations after typical oral dosing well under one percent of the administered dose. Researchers working with quercetin in cell culture or preclinical models often dose at concentrations that don’t map cleanly to anything achievable in vivo. That gap creates a reproducibility problem that the literature is quietly littered with.

On mechanism, the multi-target profile sounds appealing: mast cell stabilization, NF-kB inhibition, antioxidant activity, Bcl-family modulation. In practice, that breadth is as much a research liability as an asset. When a compound does five things at once, attributing an effect to any one of them is methodologically hard. Most of the preclinical literature leans on this ambiguity rather than resolving it.

We think quercetin has a legitimate home in any senolytic research program as a reference tool and as the Q in D+Q studies. If you’re building a senolytic protocol from scratch and you’re not running D+Q specifically, fisetin is the more defensible choice at the bench right now. Quercetin isn’t junk. It’s an established, actively-studied compound with a real but secondary role in the most important research regimen in its class, and a score in the upper-30s reflects exactly that.

Novelty

28

Mechanism promise

45

In-category differentiation

27

Evidence quality

50

Translational signal

40

Research bench value

44

Rationale Quercetin escapes the OTC food/herb cap because the senolytic indication is a real, clinically-tested research angle with Mayo Clinic trials behind it, not a generic supplement claim. Scores land in the high-30s because the compound is genuinely useful within the D+Q protocol, but on every axis it’s the weaker partner: weaker senolytic than fisetin, poor oral bioavailability, and most of the clinical signal is inseparable from dasatinib’s contribution.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Flavonoid senolytic / mast cell stabilizer

A widely distributed flavonoid with weaker senolytic activity than fisetin, often combined with dasatinib in the canonical D+Q senolytic regimen.

Abstract

Quercetin (3,3′,4′,5,7-pentahydroxyflavone; CAS 117-39-5; molecular formula C15H10O7; molecular weight 302.24) is a widely distributed flavonoid present in onions, apples, capers, and many other plants. The compound has multiple mechanisms of pharmacological interest: mast cell stabilization (anti-allergic effects), direct antioxidant activity, anti-inflammatory effects through NF-kB inhibition, and senolytic activity (in combination with the kinase inhibitor dasatinib in the canonical D+Q regimen developed by Kirkland and Niedernhofer). The senolytic activity of quercetin alone is modest; the dasatinib combination is substantially more effective. Bioavailability is poor as the free aglycone but better as the rutinose glycoside; plasma quercetin concentrations after oral dosing are typically less than 1 percent of the dose. Doses range from 500 mg to 2 grams per day; the senolytic D+Q regimen uses pulsatile dosing of 1000 to 1500 mg quercetin with 100 mg dasatinib for 2 to 3 days monthly.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-100Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
NMN (Nicotinamide Mononucleotide)

Plain-language summaryIntrigue 72 / 100

NMN is a direct precursor to NAD+, the central energy cofactor that declines with age. Supplementation aims to restore youthful NAD+ levels. David Sinclair’s lab has been the most prominent in advancing NMN research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

40/100

NAD+ precursor with real biochemical signal but modest clinical endpoints and no clear edge over NR

The NMN story starts with Sinclair’s lab at Harvard around 2013, when they showed that raising NAD+ in aged mice could reverse vascular and metabolic aging phenotypes. That was genuinely exciting work. The problem is we’re now more than a decade into the hype cycle, and the human data hasn’t delivered the paradigm-level translation the mouse studies seemed to promise.

The mechanism is NAD+ repletion via the salvage pathway. NAMPT converts nicotinamide to NMN, NMNAT converts NMN to NAD+, and from there you’re activating sirtuins (SIRT1, SIRT3, SIRT6) and supporting PARP-mediated DNA repair. The biology is solid and well-characterized. Thats actually part of the problem: there’s not much mechanistic mystery left. The Slc12a8 direct-transport argument gave NMN a theoretical uptake advantage over NR, but Brenner’s group and others have raised credible objections, and the debate sits unresolved. When a mechanism’s most interesting remaining question is a transporter contest with a competing form, you’re in mature territory.

Where NMN loses the most ground is differentiation. NR exists, it’s cheaper, it has comparable or longer trial history, and no direct head-to-head has established clear endpoint superiority for NMN in humans. Until that resolution happens, NMN is sharing a lane it hasn’t won. The FDA’s 2022 decision to classify NMN as a drug investigation under review further complicates the supplement market picture, though for bench research purposes thats mostly noise.

The clinical evidence is mixed in the honest sense. Yoshino et al. (2021, Cell Metabolism) ran a 10-week double-blind RCT in postmenopausal prediabetic women and showed skeletal muscle NAD+ elevation and improved insulin sensitivity. Real findings, modest N. The Japanese trial cohort (Igarashi et al., among others) added data on walking speed and physiological markers in older adults. Effect sizes have been real but unimpressive on the endpoints longevity investigators care most about: cognition, inflammatory burden, functional capacity at meaningful scale. Multiple completed trials are logged at clinicaltrials.gov; the overall picture is biochemical effect confirmed, functional outcomes not yet compelling.

As a bench tool, NMN earns its place. If your research touches NAD+-dependent biology, sirtuin activation, mitochondrial function under aging conditions, or PARP activity, NMN is a legitimate probe with a decent body of methodology behind it. That bench utility is real and keeps the compound relevant even as the longevity supplement narrative has gotten ahead of the evidence.

Honestly, NMN is a legitimate research compound that got buried under supplement hype. The signal is real, the mechanism is honest, but the clinical translation hasn’t kept pace with the animal data, and NR remains a credible competitor without a clear resolution. Researchers entering the NAD+ space should design experiments that directly compare forms rather than assume NMN superiority on the basis of the Slc12a8 story alone.

Novelty

35

Mechanism promise

38

In-category differentiation

32

Evidence quality

48

Translational signal

45

Research bench value

55

Rationale NMN’s mechanism is well-understood and the NAD+ repletion story is now over a decade into the hype cycle; it scores mid-range because the biochemistry is honest, the bench utility is real, but clinical translation is modest and differentiation from NR is unresolved. No hard cap applies, but novelty and differentiation drag the overall into established-active territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

NAD+ precursor

A direct precursor of NAD+ and the molecule directly downstream of NAMPT, the rate-limiting enzyme of NAD+ salvage; popularized by David Sinclair for longevity applications.

Abstract

NMN (β-nicotinamide mononucleotide; CAS 1094-61-7; molecular formula C11H15N2O8P; molecular weight 334.22) is the immediate precursor of NAD+ in the salvage biosynthesis pathway, generated by phosphorylation of nicotinamide riboside by NRK kinases or by NAMPT-mediated condensation of nicotinamide with PRPP. NMN was popularized by David Sinclair’s group at Harvard as a longevity supplement for raising NAD+ levels, which decline with age. The compound is converted to NAD+ through NMNAT enzymes after cell uptake (presumed via Slc12a8 transporter or via dephosphorylation to NR with separate uptake). Animal studies show NMN supplementation reverses several age-related phenotypes (vascular, metabolic, neurological) by restoring NAD+ levels. Human clinical trials have shown plasma NAD+ elevation but clinical endpoint changes are modest. The compound is sold as a dietary supplement; FDA classified NMN as a drug investigation in 2022, complicating supplement market availability. Doses are typically 250 to 1000 mg per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-102Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
JZL184

Plain-language summaryIntrigue 50 / 100

JZL184 is the canonical research probe for blocking MAGL, the enzyme that breaks down the endocannabinoid 2-AG. It was developed in the Cravatt laboratory at Scripps and works by permanently inactivating the enzyme, which raises 2-AG levels and produces cannabinoid-like effects without direct receptor agonism. Animal work shows analgesic and anti-inflammatory activity, but a meaningful complication is that JZL184 also partially inhibits FAAH (about 300-fold MAGL preference), muddying interpretation of some early studies. Cleaner second-generation tools like KML29 have largely replaced it for definitive mechanism work. Not a clinical compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

55/100

The canonical covalent MAGL probe; indispensable for 2-AG signaling research but carries no clinical trajectory of its own

Look, JZL184 is one of those compounds where the story is almost entirely about what it lets you do at the bench rather than what it might eventually do in a person. Brian Cravatt’s group at Scripps published the original covalent piperidinyl-carbamate scaffold in 2009, and the compound has been the go-to MAGL inhibitor ever since. That’s roughly fifteen years of multi-lab use, which tells you something: the selectivity profile held up, the covalent mechanism turned out to be a feature rather than a liability for probe work, and nobody has made something clearly better for the specific task of irreversibly blocking MAGL while leaving FAAH intact.

The mechanism is genuinely elegant. JZL184 carbamoylates the active-site serine of MAGL, producing irreversible inactivation. The selectivity over FAAH runs about 300-fold, which is what lets investigators dissect the 2-AG arm of endocannabinoid signaling from the AEA arm without crossover noise. Thats critical: AEA and 2-AG occupy very different regulatory niches at CB1 synapses, and pharmacologically parsing them has been a long-standing methodological problem. JZL184 solved the MAGL side of that problem cleanly. The behavioral pharmacology that follows from MAGL inhibition is more THC-like than FAAH inhibition (anxiolysis, analgesia, hypothermia, catalepsy at higher doses), which reflects the higher tonic CB1 occupancy that comes from pooling 2-AG rather than AEA.

What we like here is the bench specificity. If you’re working on 2-AG-mediated retrograde signaling, CB1 synaptic plasticity, MAGL’s role in neuroinflammation, or the non-CB1 downstream targets of elevated 2-AG (GPR55, PPARs), JZL184 is probably already in your protocol. The replication record across labs is genuinely strong for a research tool compound. Papers out of Piomelli’s group, Bhatt’s group, and a long list of academic neuroscience labs have built on the Scripps scaffold without needing to re-validate the selectivity claims from scratch.

The limitations are real though. Novelty is low because the compound is mature; the research frontier using JZL184 is about what investigators do with it, not the compound itself. Translational signal is basically absent because JZL184 was never designed as a development candidate, and its irreversible mechanism creates tolerability concerns that have kept it out of clinical consideration. There is no human data and no active IND. The endocannabinoid axis it probes is extremely relevant to pain and neuroinflammation programs, but those programs are being run with next-generation reversible MAGL inhibitors like ABX-1431, not with JZL184. Honestly, that’s fine. JZL184’s job is to be the canonical probe, and it does that job very well. Score it accordingly.

Novelty

38

Mechanism promise

62

In-category differentiation

72

Evidence quality

62

Translational signal

24

Research bench value

78

Rationale JZL184 scores high on differentiation and bench value because it remains the reference-standard MAGL inhibitor after 15 years, with no serious competitor for clean irreversible 2-AG elevation in preclinical models; it scores low on novelty and translational signal because the compound itself is mature and has never entered human development, functioning purely as a tool rather than a drug candidate.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective MAGL inhibitor (research)

A covalent inhibitor of monoacylglycerol lipase (MAGL); the canonical research probe for elevating endogenous 2-AG.

Abstract

JZL184 (CAS 1101854-58-3; molecular formula C27H24F2N2O5; molecular weight 510.49) is a covalent piperidinyl-carbamate inhibitor of monoacylglycerol lipase (MAGL) developed by Cravatt and colleagues at Scripps. The compound carbamoylates the active-site serine of MAGL, producing irreversible enzyme inactivation. Selective for MAGL over FAAH (approximately 300-fold) and other serine hydrolases. Pharmacological consequence: elevation of endogenous 2-AG (the principal full-agonist endocannabinoid) without direct CB receptor agonism. Behavioral effects are more THC-like than FAAH inhibition (anxiolysis, analgesia, hypothermia, catalepsy at high dose), reflecting the higher tonic CB1 occupancy from elevated 2-AG. Used as the canonical MAGL inhibitor in academic neuroscience for studies of 2-AG signaling and CB1-mediated synaptic plasticity. No human clinical development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-330Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cutamesine (SA-4503)

Our opinion on this compoundNiche research probe

54/100

Cleanest sigma-1 probe available; real bench utility but modest and mixed clinical results keep the ceiling low

Look, sigma-1 is genuinely interesting biology. It’s not a traditional receptor. It’s a chaperone protein sitting at the mitochondria-associated ER membrane, regulating IP3 receptors, calcium transfer between organelles, and cellular stress responses. When a compound engages sigma-1, you’re not turning a GPCR on or off. You’re modulating a protein that helps the cell manage ER stress and mitochondrial calcium homeostasis. Thats a different kind of pharmacology, and it opens angles that conventional receptor agonism doesn’t reach.

SA-4503 is the cleanest tool you can buy for studying that biology. Ki of roughly 17 nM at sigma-1 with greater than 100-fold selectivity over sigma-2, and minimal off-target binding beyond that. Most sigma-1 ligands are messy. Fluvoxamine hits sigma-1 but it’s primarily an SSRI, so you can’t attribute any effect cleanly. PRE-084 has been used in academic labs but SA-4503 has become the canonical reference compound precisely because the selectivity story is tight. If your hypothesis is sigma-1 mediated, this is the compound you need to run it cleanly.

Here’s the thing: the clinical picture muddies the enthusiasm considerably. The phase 2 ischemic stroke trial (60 mg, starting within 72 hours, 28 days) showed modest improvement. The MDD phase 2 results were mixed. We don’t see the kind of signal here that makes an investigator want to restructure a research program around the target. Sigma-1’s role in neuroprotection has generated decades of preclinical work and the bench-to-clinic arrow is weaker than the mechanistic story implies. That gap is real and honestly we don’t have a clean explanation for it yet.

What keeps the score from dropping further is exactly that bench utility. Sigma-1 has been pulled into COVID-19 biology (the virus binds sigma-1 through the ORF9c protein), neurodegeneration, addiction circuits, and pain processing. If you’re running any of those programs and you want a clean pharmacological probe to dissect sigma-1 contribution, SA-4503 is irreplaceable. It’s not that the compound is exciting in the way that a novel triple agonist or a mitochondrial peptide is exciting. It’s that for a specific class of research questions, its the only rigorous tool.

We think this lands firmly in niche-probe territory. Dont buy it unless sigma-1 is already in your hypothesis. If it is, dont buy anything else.

Novelty

40

Mechanism promise

60

In-category differentiation

68

Evidence quality

50

Translational signal

38

Research bench value

72

Rationale SA-4503 scores primarily on differentiation and bench value: it’s the canonical selective sigma-1 agonist and nothing else comes close on selectivity, which matters if you’re running a sigma-1 program. But the sigma-1 story is decades old, phase 2 results in both stroke and MDD were modest to mixed, and the indication space is specialized enough that most investigators won’t touch it unless sigma-1 is already in their hypothesis.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective sigma-1 receptor agonist

A selective sigma-1 receptor agonist developed for ischemic stroke recovery and major depressive disorder.

Abstract

Cutamesine (SA-4503; CAS 165377-44-6; molecular formula C19H30N2O2; molecular weight 318.45) is a selective sigma-1 receptor agonist developed at Santen Pharmaceutical and licensed to M’s Science. The compound has high sigma-1 affinity (Ki approximately 17 nM) with greater than 100-fold selectivity over sigma-2 and minimal off-target binding. Sigma-1 is a chaperone protein at the mitochondria-associated ER membrane that modulates ion channels, calcium signaling, and stress response. Phase 2 trials in ischemic stroke recovery (60 mg, 28 days starting within 72 hours of stroke) showed modest improvement; phase 2 in MDD showed mixed efficacy. Plasma half-life is approximately 5 hours. The compound is the cleanest available research probe for sigma-1 pharmacology. Used as the canonical selective sigma-1 agonist in academic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-332Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
KML29

Plain-language summaryIntrigue 48 / 100

KML29 is the second-generation cleanup of JZL184 from the same Cravatt laboratory, with about 4000-fold selectivity for MAGL over FAAH instead of the 300-fold of its predecessor. That extra cleanliness matters for research because it lets investigators raise endogenous 2-AG without simultaneously raising anandamide, isolating the contribution of each endocannabinoid. It is used purely as a research tool to study MAGL biology in pain, inflammation, and neurodegeneration, and has not been advanced to clinical trials. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

50/100

Clean selective MAGL probe that solves JZL184’s FAAH crossover problem, confined to preclinical use

Look, KML29 is exactly what it says it is: a second-generation covalent MAGL inhibitor built to solve a specific problem that JZL184 created. The problem being FAAH crossover. JZL184 was a breakthrough when the Cravatt lab introduced it; suddenly investigators had a way to elevate 2-AG without disrupting the whole endocannabinoid system. But at only 300-fold MAGL/FAAH selectivity, any study using JZL184 at decent concentrations had to grapple with whether observed effects were genuinely MAGL-mediated or partly FAAH. Thats a real mechanistic headache, and it muddied a lot of otherwise well-designed preclinical work.

KML29 fixes that. The greater-than-4000-fold selectivity is a genuine improvement and it came from systematic medicinal chemistry out of the same Cravatt group (Niphakis et al., 2013). The carbamoylation mechanism targeting MAGL’s active-site serine is identical to JZL184; this isnt a novel mechanism, it’s a selectivity upgrade. The pharmacology is well characterized across rodent models: oral bioavailability, reasonable CNS penetration, and the irreversible binding means sustained MAGL suppression from a single dose, which suits certain experimental timelines. Selectivity profiling against other serine hydrolases is solid enough that it’s become a go-to tool when investigators need a clean readout.

What we like: the bench value is real. If you’re studying pain, neuroinflammation, or the specific contribution of 2-AG tone (as opposed to AEA and FAAH-derived signals), KML29 gives you a cleaner dissection instrument than anything else currently in the academic toolkit. Multiple groups have explicitly switched from JZL184 to KML29 to attribute effects to MAGL without the FAAH noise. In neuropathic pain models, neuroinflammation studies, and some neuropsychiatric work around anxiety and stress circuitry, KML29 has produced mechanistically interpretable results where JZL184 introduced ambiguity. That’s exactly what a good probe compound should do.

What we dont love: it’s a tool compound, full stop. No clinical development for KML29 itself exists, and the broader MAGL inhibitor pipeline (Abide/Lundbeck’s ABX-1431 in Tourette syndrome, for instance) uses entirely different scaffolds optimized for human PK. KML29 has done its job in the academic literature, and the field has mostly moved on to more indication-specific probes. The evidence base is multi-lab but preclinical only, and the endocannabinoid space is mature enough that deploying KML29 doesn’t generate the kind of foundational new knowledge it would have a decade ago.

Honestly, 50 reflects this profile exactly: genuine bench value in a well-defined niche, modest novelty for a compound that’s been in circulation since 2013, solid mechanistic rationale, and zero clinical translation signal. Worth having in the library for programs centered on endocannabinoid biology. Much less compelling if that isnt your research focus.

Novelty

40

Mechanism promise

55

In-category differentiation

65

Evidence quality

45

Translational signal

30

Research bench value

70

Rationale KML29 earns its score as a highly selective covalent MAGL tool that genuinely improves on JZL184’s FAAH crossover limitation; bench value is real and well-documented across multiple labs, but the compound has no clinical development pathway and the endocannabinoid field has largely moved to indication-specific probes.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective MAGL inhibitor (second-generation)

A second-generation covalent MAGL inhibitor with improved selectivity over FAAH.

Abstract

KML29 (CAS 1366507-82-3; molecular formula C27H24F4N2O4; molecular weight 516.49) is a second-generation covalent MAGL inhibitor developed by Cravatt and colleagues. The compound has improved selectivity for MAGL over FAAH (greater than 4000-fold) compared to JZL184 (300-fold), reducing the off-target FAAH inhibition that complicated interpretation of some JZL184 studies. Mechanism is the same as JZL184: irreversible carbamoylation of MAGL’s active-site serine. Used in academic research where clean MAGL inhibition without FAAH crossover is required. No human clinical development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-331Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Anavex 2-73 (Blarcamesine)

Our opinion on this compoundNovel, promising

60/100

Multi-target sigma-1/muscarinic agonist with genuine Phase 3 Rett syndrome signal and real probe utility in neurodegeneration

Yeah, so blarcamesine isn’t the flashiest thing on the shelf, but it’s doing something that a lot of sigma-1 programs have talked about without actually delivering: it has real clinical confirmation. The EXCELLENCE Phase 3 trial in Rett syndrome reported positive results in 2024, which matters because Rett is a brutal, high-unmet-need condition and the CNS literature is littered with Phase 2 wins that collapse in Phase 3. That it held is worth noting.

The mechanism is where we spend most of our thinking. Sigma-1 receptor is a chaperone protein sitting at the ER-mitochondria interface, involved in calcium signaling, proteostasis, and ER stress modulation. It’s not a classical receptor in the GPCR sense, which makes the pharmacology more complicated and more interesting. Blarcamesine’s sigma-1 affinity sits around 860 nM, which is weaker than cutamesine but still functionally meaningful. What sets it apart is the additional muscarinic M1/M2 activity. Cholinergic deficits are central to Alzheimer’s and Parkinson’s dementia pathology, so hitting both sigma-1 chaperone biology and muscarinic tone simultaneously is a real multi-target rationale, not a coincidence of dirty pharmacology. We like that about it.

The Phase 2 data in Alzheimer’s disease and Parkinson’s disease dementia showed dose-dependent improvements on some cognitive endpoints. Honest take: the AD Phase 2 results were encouraging but not spectacular, and the trial designs had limitations. The Rett syndrome Phase 3 is the strongest evidence pillar right now. That’s a rare disease context with small N, so extrapolating broadly requires caution, but the signal is real and replicated within the program.

As a bench tool, blarcamesine has genuine value for investigators working sigma-1 neuropharmacology or probing ER stress pathways in neurodegeneration models. It’s more pharmacologically interesting than generic sigma-1 ligands precisely because of the muscarinic overlay. If you’re trying to untangle sigma-1-dependent vs. cholinergic contributions to a cellular phenotype, blarcamesine gives you a handle that simpler probes dont. Cutamesine (SA4503) had its Phase 2 stroke trial fail, and fluvoxamine’s sigma-1 activity is inseparable from its SERT pharmacology. Blarcamesine is the most clinically advanced compound with a specific dual sigma-1/muscarinic profile, which gives it differentiation that isnt just theoretical.

What we dont love: the sigma-1 field has been promising a lot for twenty-plus years and the clinical wins have been narrow and indication-specific so far. The Alzheimer’s program needs Phase 3 to answer the real question. But the 2024 Rett result adds legitimacy to the mechanism, and the compound’s probe utility in ER stress and cholinergic neurobiology is solid. For a lab working neurodegeneration or protein homeostasis, this earns a place on the shelf.

Novelty

55

Mechanism promise

65

In-category differentiation

62

Evidence quality

60

Translational signal

62

Research bench value

55

Rationale Blarcamesine’s dual sigma-1/muscarinic profile is meaningfully differentiated from single-target sigma-1 ligands, and the 2024 Phase 3 EXCELLENCE trial positive result in Rett syndrome is the clearest clinical confirmation in its class; however, the Alzheimer’s Phase 2 data is modest and sigma-1 receptor biology, while genuinely interesting, has been pursued since the 1990s, which constrains novelty and mechanism scores.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sigma-1 agonist + muscarinic modulator

A sigma-1 agonist with muscarinic acetylcholine receptor activity; investigated for Alzheimer disease, Parkinson dementia, and Rett syndrome.

Abstract

Anavex 2-73 (blarcamesine, AVN-101; CAS 195615-83-9; molecular formula C16H21NO; molecular weight 243.34) is a multi-target sigma-1 agonist with muscarinic acetylcholine receptor activity, developed by Anavex Life Sciences. Sigma-1 affinity is approximately 860 nM (lower than cutamesine but functionally meaningful); the compound additionally interacts with muscarinic M1 and M2 receptors. Phase 2 trials in Alzheimer disease and Parkinson disease dementia demonstrated dose-dependent improvements in some cognitive endpoints. Phase 3 in Rett syndrome (EXCELLENCE trial) reported positive results in 2024 for select endpoints. Plasma half-life is approximately 14 hours. Used as a multi-target research compound for sigma-1 and muscarinic neuropharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-333Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pinoline

Plain-language summaryIntrigue 40 / 100

Pinoline is a methoxylated tetrahydro-beta-carboline that the body makes endogenously, found in pineal gland and brain tissue. Biosynthetically it sits between the tryptamines (DMT, 5-MeO-DMT) and melatonin, which has fueled the long-disputed hypothesis that the pineal gland produces endogenous psychedelic compounds (the so-called DMT-pineal theory associated with Rick Strassman). Pharmacologically it is a weak reversible MAO-A inhibitor and a weak serotonin reuptake inhibitor. Concrete physiological function remains speculative, with most claims resting on tissue distribution and conjecture rather than controlled human studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

32/100

Niche endogenous beta-carboline with contested pineal biology and a very thin evidence base

Pinoline sits at a genuinely interesting intersection: it’s endogenous, it comes from the pineal gland, and it’s biosynthetically adjacent to the tryptamine family in a way that gets researchers excited about what it might be doing in vivo. We get that appeal. But when you actually dig into the pharmacology and the evidence base, the picture gets much murkier.

The mechanism is dual but weak. MAO-A inhibition (reversible, low potency) plus serotonin reuptake inhibition – neither of these is novel, and at the concentrations pinoline appears at endogenously, the functional significance is genuinely unclear. The compound has been implicated in the contested endogenous psychedelic hypothesis alongside DMT and 5-MeO-DMT, but this remains exactly that: a hypothesis. There’s no clean mechanistic story that says pinoline does X in the pineal at Y concentration and this matters for anything measurable.

The evidence problem is serious. Human pharmacokinetics are sparsely documented – the monograph says so directly, and thats not a small caveat, thats the whole ballgame for translational relevance. Most of the interesting preclinical work is old, small, and poorly replicated. There’s no equivalent of the Croatia-based BPC-157 group or the Khavinson lab anchoring a body of literature here. Multi-lab replication of the more interesting mechanistic claims is essentially absent.

Translational signal is correspondingly weak. Detection in pineal and brain tissue establishes endogenous presence but doesnt establish physiological role. The gap between found it there and it does this in humans remains very wide, and there’s no serious clinical program trying to close it. Contrast this with MOTS-c or SS-31, where the endogenous origin story is paired with a defined mitochondrial mechanism and real phase 2 data.

What pinoline has going for it is narrow but real probe value. If your lab is working on endogenous beta-carboline chemistry, MAO-A biology in a tryptaminergic context, or the broader contested field of pineal-derived signaling, pinoline is a useful reference compound. The biosynthetic relationship to melatonin and the structural adjacency to N,N-DMT give it genuine interest as a tool for mapping that chemical space. Thats a legitimate use case.

Honestly, the compound scores where it scores because the research space it occupies is real but small, the evidence is thin, the mechanism is not particularly elegant, and the translational gap is wide. For a lab specifically investigating beta-carboline pharmacology or endogenous pineal chemistry, it earns a place on the shelf. For anyone else, there are higher-signal targets in almost every adjacent category.

Novelty

40

Mechanism promise

32

In-category differentiation

40

Evidence quality

22

Translational signal

18

Research bench value

40

Rationale Weak dual MAO-A/SRI mechanism with low endogenous concentrations and unclear physiological role; evidence is sparse and poorly replicated, limiting scores heavily on evidence quality and translational signal; bench value is real but narrow, confined to labs specifically investigating beta-carboline or pineal-derived signaling chemistry.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous beta-carboline (6-methoxy-tetrahydro-beta-carboline)

An endogenous methoxylated tetrahydro-beta-carboline; a methylated tryptamine derivative implicated in pineal gland function.

Abstract

Pinoline (6-methoxy-1,2,3,4-tetrahydro-beta-carboline, 6-MeO-THBC; CAS 20684-89-1; molecular formula C12H14N2O; molecular weight 202.25) is an endogenous beta-carboline alkaloid identified in pineal gland and brain tissue. The compound is biosynthetically related to melatonin and to the tryptamines (DMT, 5-MeO-DMT) and is hypothesized to participate in endogenous psychoactivity (the contested DMT-pineal hypothesis). Pharmacologically, pinoline is a weak reversible MAO-A inhibitor and a serotonin reuptake inhibitor; the in vivo concentrations are low and its physiological role is incompletely characterized. Plasma half-life and pharmacokinetics in humans are sparsely documented. Used as a research probe for endogenous beta-carboline chemistry and pineal-gland-derived signaling.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-336Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 53 54 55 56 57 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.